Table 2.
Univariate and multivariate analysis of disease-free survival in patients with CRC.
| Univariate analysis |
Multivariate analysis |
|||
|---|---|---|---|---|
| Variables | HR (95% CI) | P | HR (95% CI) | P |
| Sex (male vs. female) | 1.581 (0.832–3.004) | 0.162 | ||
| Age (≥ 60 vs. < 60) | 1.158 (0.618–2.171) | 0.647 | ||
| Primary tumor (right- vs. left-sided colon vs. rectum) | 1.072 (0.745–1.543) | 0.707 | ||
| Histology (poorly vs. well/moderate) | 1.000 (0.518–1.931) | 0.999 | ||
| T stage (4 vs. 3, 2, 1) | 2.014 (1.127–3.599) | 0.018a | 2.139 (1.192–3.838) | 0.011a |
| N stage (2 vs. 1 vs. 0) | 1.387 (0.900–2.138) | 0.139 | ||
| TNM stage (III, IV vs. II) | 1.357 (0.689–2.672) | 0.378 | ||
| Chemotherapy regimen (CAPOX, Capecitabine vs. FOLFOX) | 0.688(0.372–1.273) | 0.234 | ||
| Duration of chemotherapy (> 20 weeks vs. < 20 weeks) | 0.556(0.312–0.992) | 0.047a | 0.566 (0.317–1.013) | 0.055 |
| Treatment (CIK vs. control) | 0.399 (0.215–0.741) | 0.004a | 0.399 (0.214–0.743) | 0.004a |
HR, Hazard ratio; CI, confidence interval; CRC, colorectal cancer; CAPOX, Capecitabine + Oxaliplatin; FOLFOX, Oxaliplatin + 5-fluorouracil; CIK, cytokine-induced killer cell.
aP value < 0.05